These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 23305268)

  • 1. Long-term etanercept therapy favors weight gain and ameliorates cachexia in rheumatoid arthritis patients: roles of gut hormones and leptin.
    Chen CY; Tsai CY; Lee PC; Lee SD
    Curr Pharm Des; 2013; 19(10):1956-64. PubMed ID: 23305268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis.
    Marcora SM; Chester KR; Mittal G; Lemmey AB; Maddison PJ
    Am J Clin Nutr; 2006 Dec; 84(6):1463-72. PubMed ID: 17158431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
    Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects of anti-tumour necrosis factor therapy on weight in patients with rheumatoid arthritis.
    Brown RA; Spina D; Butt S; Summers GD
    Clin Rheumatol; 2012 Mar; 31(3):455-61. PubMed ID: 22009196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report.
    Catrina AI; Trollmo C; af Klint E; Engstrom M; Lampa J; Hermansson Y; Klareskog L; Ulfgren AK
    Arthritis Rheum; 2005 Jan; 52(1):61-72. PubMed ID: 15641091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis.
    Chen HA; Lin KC; Chen CH; Liao HT; Wang HP; Chang HN; Tsai CY; Chou CT
    Ann Rheum Dis; 2006 Jan; 65(1):35-9. PubMed ID: 15975966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etanercept reduces the serum levels of macrophage chemotactic protein-1 in patients with rheumatoid arthritis.
    Kageyama Y; Kobayashi H; Kato N; Shimazu M
    Mod Rheumatol; 2009; 19(4):372-8. PubMed ID: 19458908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis.
    Catrina AI; Lampa J; Ernestam S; af Klint E; Bratt J; Klareskog L; Ulfgren AK
    Rheumatology (Oxford); 2002 May; 41(5):484-9. PubMed ID: 12011369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etanercept decreases synovial expression of tumour necrosis factor-α and lymphotoxin-α in rheumatoid arthritis.
    Neregård P; Krishnamurthy A; Revu S; Engström M; af Klint E; Catrina AI
    Scand J Rheumatol; 2014; 43(2):85-90. PubMed ID: 24313444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etanercept: therapeutic use in patients with rheumatoid arthritis.
    Garrison L; McDonnell ND
    Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I65-9. PubMed ID: 10577976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis.
    Zivojinovic SM; Pejnovic NN; Sefik-Bukilica MN; Kovacevic LV; Soldatovic II; Damjanov NS
    J Rheumatol; 2012 Jan; 39(1):18-21. PubMed ID: 22133625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etanercept normalises left ventricular mass in patients with rheumatoid arthritis.
    Daïen CI; Fesler P; du Cailar G; Daïen V; Mura T; Dupuy AM; Cristol JP; Ribstein J; Combe B; Morel J
    Ann Rheum Dis; 2013 Jun; 72(6):881-7. PubMed ID: 22872022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
    Catrina AI; af Klint E; Ernestam S; Catrina SB; Makrygiannakis D; Botusan IR; Klareskog L; Ulfgren AK
    Arthritis Rheum; 2006 Jan; 54(1):76-81. PubMed ID: 16385498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of anti-tumor necrosis factor (TNF)-alpha therapy with etanercept on endothelial functions in patients with rheumatoid arthritis.
    Tikiz H; Arslan O; Pirildar T; Tikiz C; Bayindir P
    Anadolu Kardiyol Derg; 2010 Apr; 10(2):98-103. PubMed ID: 20382605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed treatment with tumor necrosis factor inhibitors in incomplete responders to synthetic disease-modifying anti-rheumatic drugs shows an excellent effect in patients with very early rheumatoid arthritis with poor prognosis factors.
    Kita J; Tamai M; Arima K; Nakashima Y; Suzuki T; Kawashiri SY; Okada A; Koga T; Yamasaki S; Nakamura H; Origuchi T; Aramaki T; Nakashima M; Fujikawa K; Tsukada T; Ida H; Aoyagi K; Uetani M; Eguchi K; Kawakami A
    Mod Rheumatol; 2012 Apr; 22(2):195-201. PubMed ID: 21898075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies.
    Schiff MH; Yu EB; Weinblatt ME; Moreland LW; Genovese MC; White B; Singh A; Chon Y; Woolley JM
    Drugs Aging; 2006; 23(2):167-78. PubMed ID: 16536638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety and efficacy of etanercept on cardiac functions and lipid profile in patients with active rheumatoid arthritis.
    Senel S; Cobankara V; Taskoylu O; Karasu U; Karapinar H; Erdis E; Evrengul H; Kaya MG
    J Investig Med; 2012 Jan; 60(1):62-5. PubMed ID: 22064606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis.
    Goldenberg MM
    Clin Ther; 1999 Jan; 21(1):75-87; discussion 1-2. PubMed ID: 10090426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept.
    Fleischmann R; Iqbal I; Nandeshwar P; Quiceno A
    Drug Saf; 2002; 25(3):173-97. PubMed ID: 11945114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.